Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bruker Corporation stock logo
BRKR
Bruker
$58.31
+7.2%
$39.65
$28.53
$58.49
$8.86B1.122.36 million shs3.25 million shs
Icon Plc stock logo
ICLR
Icon
$137.60
+0.6%
$112.28
$66.57
$211.00
$11.15B1.231.59 million shs759,051 shs
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$183.14
+1.1%
$170.04
$136.41
$247.04
$30.53B1.181.91 million shs536,410 shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$451.47
+0.7%
$457.62
$291.28
$628.92
$12.94B1.19366,701 shs94,510 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bruker Corporation stock logo
BRKR
Bruker
+11.87%+20.92%+50.00%+35.60%+47.12%
Icon Plc stock logo
ICLR
Icon
+15.49%+17.35%+33.48%+26.50%+4.56%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
+9.00%+7.77%+13.76%+1.02%+30.54%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
+4.70%+4.19%+9.32%-0.81%+52.52%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bruker Corporation stock logo
BRKR
Bruker
$58.31
+7.2%
$39.65
$28.53
$58.49
$8.86B1.122.36 million shs3.25 million shs
Icon Plc stock logo
ICLR
Icon
$137.60
+0.6%
$112.28
$66.57
$211.00
$11.15B1.231.59 million shs759,051 shs
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$183.14
+1.1%
$170.04
$136.41
$247.04
$30.53B1.181.91 million shs536,410 shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$451.47
+0.7%
$457.62
$291.28
$628.92
$12.94B1.19366,701 shs94,510 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bruker Corporation stock logo
BRKR
Bruker
+11.87%+20.92%+50.00%+35.60%+47.12%
Icon Plc stock logo
ICLR
Icon
+15.49%+17.35%+33.48%+26.50%+4.56%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
+9.00%+7.77%+13.76%+1.02%+30.54%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
+4.70%+4.19%+9.32%-0.81%+52.52%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bruker Corporation stock logo
BRKR
Bruker
2.47
Hold$50.54-13.32% Downside
Icon Plc stock logo
ICLR
Icon
2.22
Hold$151.6710.22% Upside
IQVIA Holdings Inc. stock logo
IQV
IQVIA
3.00
Buy$225.6923.23% Upside
Medpace Holdings, Inc. stock logo
MEDP
Medpace
2.20
Hold$467.083.46% Upside

Current Analyst Ratings Breakdown

Latest IQV, BRKR, ICLR, and MEDP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2026
Icon Plc stock logo
ICLR
Icon
Set Price TargetHold$139.00 ➝ $159.00
5/29/2026
Icon Plc stock logo
ICLR
Icon
Reiterated RatingBuy$165.00
5/29/2026
Icon Plc stock logo
ICLR
Icon
Boost Price TargetSector Perform$123.00 ➝ $126.00
5/29/2026
Icon Plc stock logo
ICLR
Icon
Boost Price TargetNeutral$120.00 ➝ $130.00
5/29/2026
Icon Plc stock logo
ICLR
Icon
Boost Price TargetEqual Weight$120.00 ➝ $150.00
5/29/2026
Icon Plc stock logo
ICLR
Icon
Boost Price TargetOutperform$130.00 ➝ $160.00
5/28/2026
Icon Plc stock logo
ICLR
Icon
DowngradeNeutral
5/28/2026
Icon Plc stock logo
ICLR
Icon
Set Price Target$145.00
5/27/2026
Icon Plc stock logo
ICLR
Icon
Reiterated RatingUnderperform$105.00
5/18/2026
Icon Plc stock logo
ICLR
Icon
Lower Price TargetNeutral$175.00 ➝ $120.00
5/11/2026
Bruker Corporation stock logo
BRKR
Bruker
DowngradeSell (D+)Sell (D)
(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bruker Corporation stock logo
BRKR
Bruker
$3.46B2.57$4.05 per share14.40$16.21 per share3.60
Icon Plc stock logo
ICLR
Icon
$8.25B1.35$23.28 per share5.91$117.92 per share1.17
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$16.31B1.87$19.76 per share9.27$38.04 per share4.81
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$2.53B5.10$17.94 per share25.16$20.95 per share21.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bruker Corporation stock logo
BRKR
Bruker
-$8.60M-$0.24N/A24.502.91-0.65%11.60%4.25%8/4/2026 (Estimated)
Icon Plc stock logo
ICLR
Icon
$791.47M$7.3922.4110.513.097.40%10.58%6.01%7/22/2026 (Estimated)
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$1.36B$8.0722.6714.171.588.33%30.50%6.53%7/28/2026 (Estimated)
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$451.12M$15.9128.4824.352.1717.19%120.89%24.79%7/20/2026 (Estimated)

Latest IQV, BRKR, ICLR, and MEDP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/27/2026Q1 2026
Icon Plc stock logo
ICLR
Icon
$2.95$2.52-$0.43$1.93$1.98 billion$2.11 billion
5/6/2026Q1 2026
Bruker Corporation stock logo
BRKR
Bruker
$0.23$0.31+$0.08$0.02$795.62 million$823.40 million
5/5/2026Q1 2026
IQVIA Holdings Inc. stock logo
IQV
IQVIA
$2.83$2.90+$0.07$1.61$4.10 billion$4.15 billion
4/22/2026Q1 2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$3.74$4.28+$0.54$4.28$697.82 million$706.60 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bruker Corporation stock logo
BRKR
Bruker
$0.200.34%+4.56%N/A N/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
IQVIA Holdings Inc. stock logo
IQV
IQVIA
N/AN/AN/AN/AN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/AN/AN/AN/AN/A

Latest IQV, BRKR, ICLR, and MEDP Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/14/2026
Bruker Corporation stock logo
BRKR
Bruker
quarterly$0.050.47%6/22/20266/22/20267/7/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bruker Corporation stock logo
BRKR
Bruker
0.67
1.55
0.72
Icon Plc stock logo
ICLR
Icon
0.31
1.06
1.06
IQVIA Holdings Inc. stock logo
IQV
IQVIA
2.20
0.75
0.75
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/A
0.85
0.85

Institutional Ownership

CompanyInstitutional Ownership
Bruker Corporation stock logo
BRKR
Bruker
79.52%
Icon Plc stock logo
ICLR
Icon
95.61%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
89.62%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
77.98%

Insider Ownership

CompanyInsider Ownership
Bruker Corporation stock logo
BRKR
Bruker
27.20%
Icon Plc stock logo
ICLR
Icon
44.00%
IQVIA Holdings Inc. stock logo
IQV
IQVIA
1.70%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
20.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bruker Corporation stock logo
BRKR
Bruker
11,085152.23 million110.82 millionOptionable
Icon Plc stock logo
ICLR
Icon
41,90080.76 million45.22 millionOptionable
IQVIA Holdings Inc. stock logo
IQV
IQVIA
93,000166.90 million164.06 millionOptionable
Medpace Holdings, Inc. stock logo
MEDP
Medpace
6,20028.56 million22.71 millionOptionable

Recent News About These Companies

Medpace Holdings, Inc. $MEDP Shares Sold by Swedbank AB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bruker stock logo

Bruker NASDAQ:BRKR

$58.30 +3.92 (+7.20%)
As of 02:15 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Icon stock logo

Icon NASDAQ:ICLR

$137.60 +0.80 (+0.58%)
As of 02:15 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

IQVIA stock logo

IQVIA NYSE:IQV

$183.14 +2.05 (+1.13%)
As of 02:15 PM Eastern
This is a fair market value price provided by Massive. Learn more.

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Medpace stock logo

Medpace NASDAQ:MEDP

$451.46 +3.35 (+0.75%)
As of 02:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.